OncoMatch/Clinical Trials/NCT06773845
Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria
Is NCT06773845 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies TheraSphere for hepatocellular carcinoma (hcc).
Treatment: TheraSphere — At four major centers in Korea, patients with hepatocellular carcinoma (HCC) that exceed the up-to-7 criteria yet remain locally confined will undergo ablative radioembolization using Yttrium-90 glass microspheres, guided by a standardized dosimetry method. Their treatment response, survival outcomes, and adverse events will be monitored for two years following the procedure.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Blood counts
Leukocytes ≥ 2,000/µL and ≤ 15,000/µL; Hemoglobin ≥ 8.0 g/dL (transfusion allowed); Platelet ≥ 40,000/µL; INR ≤ 2.0 for patients not taking anticoagulants
Kidney function
Creatinine ≤ 2.5 mg/dL
Liver function
Total bilirubin ≤ 2.0 mg/dL; AST ≤ 200 IU/L (≤ 5X upper normal limit); ALT ≤ 200 IU/L (≤ 5X upper normal limit)
No major organ dysfunction according to blood test performed within two months of study enrollment: * Leukocytes ≥ 2,000/µL and ≤ 15,000/µL * Hemoglobin ≥ 8.0 g/dL (transfusion allowed to meet this criterion) * Total bilirubin ≤ 2.0 mg/dL * Platelet ≥ 40,000/µL * International normalized ratio (INR) ≤ 2.0 for patients not taking anticoagulants * Aspartate transaminase (AST) ≤ 200 IU/L (i.e., ≤ 5X upper normal limit) * Alanine transaminase (ALT) ≤ 200 IU/L (i.e., ≤ 5X upper normal limit) * Creatinine ≤ 2.5 mg/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06773845 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages